As a Venture Capital, DAYLI Partners invests in prospective private
bio-ventures home and abroad. Investment
decisions are made
based on the founder’s competence, management team, technology, and
valuation.
Investments are made across all stages of a
bio-venture’s life, ranging from Series A to pre-IPO. Moreover,
DAYLI Partners invests in all sectors within the bio-healthcare
industry, including therapeutics, life sciences, medical devices,
and diagnostics.
Deal sourcing of promising and competent startups with the perspective of capital markets
Valuation-Based Entry & Exit Judgments
Pre-emptive investments in competent
startups through
early deal sourcing
Value adding activities that maximize
the investee
company’s value
Top-down and bottom-up deal sourcing based on the understanding
of macro and micro environments
Portfolio Management Experience
Selection of competent companies that fit the global trend
Investments in First in Class and Best in Class R&D Companies
Investments in companies under-valued compared to peer groups
Follow On Investments
Higher
stability for rate of return
